Open Access

Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

  • Authors:
    • Kazuhiko Kasuya
    • Yuichi Nagakawa
    • Minako Suzuki
    • Yoshiaki Suzuki
    • Bunso Kyo
    • Satoru Suzuki
    • Takaaki Matsudo
    • Takao Itoi
    • Akihiko Tsuchida
    • Tatsuya Aoki
  • View Affiliations

  • Published online on: January 18, 2012     https://doi.org/10.3892/etm.2012.456
  • Pages: 599-602
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We previously reported that the administration of bevacizumab for pancreatic neuroendocrine tumors inhibited angiogenesis in the host, resulting in tumor growth inhibition. In light of these results, we compared the effect of bevacizumab/gemcitabine/S-1 combination therapy vs. bevacizumab monotherapy. The QGP-1 pancreatic neuroendocrine carcinoma cell line and the BxPC-3 ductal cell carcinoma cell line were transplanted into the subcutaneous tissue of mice, and the mice were treated for 3 weeks with bevacizumab [50 mg/kg intraperitoneally (i.p.) twice weekly], gemcitabine (240 mg/kg i.p. once weekly) and S-1 (10 mg/kg orally five times weekly). The antitumor effect and side effects were evaluated by measuring the tumor volume and weight and by changes in body weight, respectively. The tumor volume became smaller (from the maximum volume) in the group treated with bevacizumab, gemcitabine and S-1 (BGS) and the group treated with bevacizumab and gemcitabine (BG). A significant difference was noted in the tumor weight between the BG group and the group treated with bevacizumab alone. A relatively significant decrease in the body weight was observed in the BGS and BG groups. We conclude that gemcitabine is appropriate as a drug used in combination with bevacizumab for pancreatic neuroendocrine tumors.
View Figures
View References

Related Articles

Journal Cover

April 2012
Volume 3 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kasuya K, Nagakawa Y, Suzuki M, Suzuki Y, Kyo B, Suzuki S, Matsudo T, Itoi T, Tsuchida A, Aoki T, Aoki T, et al: Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma. Exp Ther Med 3: 599-602, 2012
APA
Kasuya, K., Nagakawa, Y., Suzuki, M., Suzuki, Y., Kyo, B., Suzuki, S. ... Aoki, T. (2012). Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma. Experimental and Therapeutic Medicine, 3, 599-602. https://doi.org/10.3892/etm.2012.456
MLA
Kasuya, K., Nagakawa, Y., Suzuki, M., Suzuki, Y., Kyo, B., Suzuki, S., Matsudo, T., Itoi, T., Tsuchida, A., Aoki, T."Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma". Experimental and Therapeutic Medicine 3.4 (2012): 599-602.
Chicago
Kasuya, K., Nagakawa, Y., Suzuki, M., Suzuki, Y., Kyo, B., Suzuki, S., Matsudo, T., Itoi, T., Tsuchida, A., Aoki, T."Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma". Experimental and Therapeutic Medicine 3, no. 4 (2012): 599-602. https://doi.org/10.3892/etm.2012.456